Abiopharma

News list

VISTAGEN THERAPEUTICS, INC. (VTGN)

SEC News
June 30, 2026, 12:28 UTC

(90% Positive) VISTAGEN THERAPEUTICS, INC. (VTGN) Announces Clinical Development Update

Full text

News bot June 30, 2026, 12:30 p.m.

📋 VISTAGEN THERAPEUTICS, INC. (VTGN) - Clinical Trial Update

Filing Date: 2026-06-30

Accepted: 2026-06-30 08:28:42

Event Type: Clinical Trial Update

Event Details:

VISTAGEN THERAPEUTICS, INC. (VTGN) Announces Clinical Trial Update VISTAGEN THERAPEUTICS, INC. (VTGN) provided an update on its clinical development programs. Clinical Development Highlights:

Drug Program: fasedienol, symptoms
Clinical Stage: Phase 3, Phase 3 trial
Collaboration: Post-Hoc Data

🔬 Clinical Development Pipeline (VISTAGEN THERAPEUTICS, INC.):

Product	Type	Development Stage	Therapeutic Area	Source
Placebo Nasal Spray	Other	Phase PHASE3	Social Anxiety Disorder (SAD)	ClinicalTrials.gov
Fasedienol Nasal Spray	Other	Phase PHASE3	Social Anxiety Disorder (SAD)	ClinicalTrials.gov
PH94B Nasal Spray	Other	Phase PHASE3	Social Anxiety Disorder	ClinicalTrials.gov
Placebo	Other	Phase PHASE1	Neuropathic Pain	ClinicalTrials.gov
AV-101	Other	Phase PHASE1	Neuropathic Pain	ClinicalTrials.gov
AV-101 1440 mg	Other	Phase PHASE1	Healthy	ClinicalTrials.gov
AV-101 720 mg	Other	Phase PHASE1	Healthy	ClinicalTrials.gov
Probenecid	Other	Phase PHASE1	Drug Drug Interaction	ClinicalTrials.gov
PH94B	Other	Phase PHASE2	Adjustment Disorder With Anxious Mood	ClinicalTrials.gov
Placebo Nasal Spray - Placebo Nasal Spray	Other	Phase PHASE2	Social Anxiety Disorder	ClinicalTrials.gov
Fasedienol Nasal Spray - Fasedienol Nasal Spray	Other	Phase PHASE2	Social Anxiety Disorder	ClinicalTrials.gov
Fasedienol Nasal Spray - Placebo Nasal Spray	Other	Phase PHASE2	Social Anxiety Disorder	ClinicalTrials.gov

💼 Business Developments:

Partnership: Not available
Acquisition: Not available
Licensing: Not available
Regulatory Approval
Executive Changes: Not available

Structured Data:

Company Name: VISTAGEN THERAPEUTICS, INC.
Ticker Symbol: VTGN